Immunohistochemical analysis of the expression of cdk4 and p16(INK4) in human endometrioid-type endometrial carcinoma

Cancer

Volumn 80, Issue 12, 1997, Pages 2250-2256

  Shiozawa, Tanri ^a   Nikaido, Toshio ^a   Shimizu, Motohiko ^a   Zhai, Yali ^a   Fujii, Shingo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinoma; cdk4; Endometrium; Immunohistochemistry; p16(INK4); Uterus

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P16;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

CARCINOMA, ENDOMETRIOID; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS;

EID: 0031456497     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971215)80:12<2250::AID-CNCR5>3.0.CO;2-Y     Document Type: Article

References (25)

1. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
2. Hartwell LH, Kasten MB. Cell cycle control and cancer. Science 1994;266:1821-8.
3. White E. p53, guardian of Rb. Nature 1994;371:21-2.
4. Sasano H, Comerford I, Silverberg SG, Carrett CT. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 1990;66:2150-4.
5. Risinger JI, Dent GA, Ingar-Trowbridge D, McLachlan JA, Tsao MS, Senterman M, et al. p53 mutations in human endometrial carcinoma. Mol Carcinog 1992;5:250-3.
6. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
7. Ambros RA, Vigna PA, Figge J, Kallakury BV, Mastrangelo A, Eastman AY, et al. Observation on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;73:1686-92.
8. Li S-F, Shiozawa T, Nakayama K, Nikaido T, Fujii S. Stepwise abnormality of sex steroid receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 1966;77:321-9.
9. Nikaido T, Li S-F, Shiozawa T, Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248-53.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ Cdk4. Nature 1993;366:704-7.
11. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
12. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
13. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the Mts1/Cdk4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54:3396-7.
14. INK4 in human cancer. Proc Natl Acad Sci U S A 1994;91:11045-9.
15. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzalez F, et al. p16 gene in uncultured tumours. Nature 1994;370:183-4.
16. INK4 of retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833-6.
17. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-83.
18. INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 1996;134:268-75.
19. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 1997;57:169-75.
20. Mittnacht S, Weinberg RA. G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 1991;65:381-93.
21. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag, 1994:447.
22. INK4A in archival human solid tumors: correlation with retinoblastoma expression. Cancer Res 1995;55:6006-11.
23. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
24. Kokeguchi S, Hayase R, Sekiba K. Proliferative activity in normal endometrium and endometrial carcinoma measured by immunohistochemistry using Ki-67 and anti-DNA polymerase alpha antibody, and by flow cytometry. Acta Med Okayama 1992;46:113-21.
25. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.